ICU Medical Competitors

Align Technology (NASDAQ:ALGN) and ICU Medical (NASDAQ:ICUI) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Institutional and Insider Ownership

85.8% of Align Technology shares are owned by institutional investors. Comparatively, 91.5% of ICU Medical shares are owned by institutional investors. 1.2% of Align Technology shares are owned by company insiders. Comparatively, 10.9% of ICU Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Align Technology and ICU Medical's net margins, return on equity and return on assets.

Risk & Volatility

Align Technology has a beta of 1.68, suggesting that its stock price is 68% more volatile than the S&P 500. Comparatively, ICU Medical has a beta of 0.72, suggesting that its stock price is 28% less volatile than the S&P 500.

Earnings and Valuation

This table compares Align Technology and ICU Medical's gross revenue, earnings per share and valuation.

Align Technology has higher revenue and earnings than ICU Medical. ICU Medical is trading at a lower price-to-earnings ratio than Align Technology, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Align Technology and ICU Medical, as provided by MarketBeat.com.

Align Technology currently has a consensus price target of $501.3333, suggesting a potential downside of 15.77%. ICU Medical has a consensus price target of $240.50, suggesting a potential upside of 15.69%. Given ICU Medical's stronger consensus rating and higher probable upside, analysts plainly believe ICU Medical is more favorable than Align Technology.

Summary

Align Technology beats ICU Medical on 8 of the 14 factors compared between the two stocks.

ICU Medical (NASDAQ:ICUI) and West Pharmaceutical Services (NYSE:WST) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for ICU Medical and West Pharmaceutical Services, as provided by MarketBeat.

ICU Medical currently has a consensus target price of $240.50, suggesting a potential upside of 15.69%. West Pharmaceutical Services has a consensus target price of $310.00, suggesting a potential upside of 2.35%. Given ICU Medical's stronger consensus rating and higher possible upside, equities analysts plainly believe ICU Medical is more favorable than West Pharmaceutical Services.

Earnings and Valuation

This table compares ICU Medical and West Pharmaceutical Services' top-line revenue, earnings per share (EPS) and valuation.

West Pharmaceutical Services has higher revenue and earnings than ICU Medical. ICU Medical is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

91.5% of ICU Medical shares are held by institutional investors. Comparatively, 92.6% of West Pharmaceutical Services shares are held by institutional investors. 10.9% of ICU Medical shares are held by insiders. Comparatively, 1.6% of West Pharmaceutical Services shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

ICU Medical has a beta of 0.72, suggesting that its share price is 28% less volatile than the S&P 500. Comparatively, West Pharmaceutical Services has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500.

Profitability

This table compares ICU Medical and West Pharmaceutical Services' net margins, return on equity and return on assets.

Summary

West Pharmaceutical Services beats ICU Medical on 9 of the 13 factors compared between the two stocks.

The Cooper Companies (NYSE:COO) and ICU Medical (NASDAQ:ICUI) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, profitability, earnings and institutional ownership.

Risk & Volatility

The Cooper Companies has a beta of 0.82, indicating that its stock price is 18% less volatile than the S&P 500. Comparatively, ICU Medical has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500.

Institutional & Insider Ownership

95.8% of The Cooper Companies shares are owned by institutional investors. Comparatively, 91.5% of ICU Medical shares are owned by institutional investors. 1.4% of The Cooper Companies shares are owned by insiders. Comparatively, 10.9% of ICU Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares The Cooper Companies and ICU Medical's top-line revenue, earnings per share and valuation.

The Cooper Companies has higher revenue and earnings than ICU Medical. ICU Medical is trading at a lower price-to-earnings ratio than The Cooper Companies, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares The Cooper Companies and ICU Medical's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current recommendations and price targets for The Cooper Companies and ICU Medical, as provided by MarketBeat.

The Cooper Companies currently has a consensus target price of $384.25, indicating a potential downside of 1.26%. ICU Medical has a consensus target price of $240.50, indicating a potential upside of 15.69%. Given ICU Medical's stronger consensus rating and higher possible upside, analysts clearly believe ICU Medical is more favorable than The Cooper Companies.

Summary

The Cooper Companies beats ICU Medical on 10 of the 14 factors compared between the two stocks.

ICU Medical (NASDAQ:ICUI) and DENTSPLY SIRONA (NASDAQ:XRAY) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation and risk.

Institutional and Insider Ownership

91.5% of ICU Medical shares are held by institutional investors. Comparatively, 96.0% of DENTSPLY SIRONA shares are held by institutional investors. 10.9% of ICU Medical shares are held by insiders. Comparatively, 0.5% of DENTSPLY SIRONA shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and price targets for ICU Medical and DENTSPLY SIRONA, as provided by MarketBeat.com.

ICU Medical presently has a consensus target price of $240.50, indicating a potential upside of 15.69%. DENTSPLY SIRONA has a consensus target price of $55.3333, indicating a potential downside of 14.87%. Given ICU Medical's stronger consensus rating and higher probable upside, equities analysts plainly believe ICU Medical is more favorable than DENTSPLY SIRONA.

Valuation & Earnings

This table compares ICU Medical and DENTSPLY SIRONA's revenue, earnings per share and valuation.

DENTSPLY SIRONA has higher revenue and earnings than ICU Medical. DENTSPLY SIRONA is trading at a lower price-to-earnings ratio than ICU Medical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares ICU Medical and DENTSPLY SIRONA's net margins, return on equity and return on assets.

Volatility & Risk

ICU Medical has a beta of 0.72, meaning that its share price is 28% less volatile than the S&P 500. Comparatively, DENTSPLY SIRONA has a beta of 0.98, meaning that its share price is 2% less volatile than the S&P 500.

Summary

ICU Medical beats DENTSPLY SIRONA on 8 of the 14 factors compared between the two stocks.

Haemonetics (NYSE:HAE) and ICU Medical (NASDAQ:ICUI) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, earnings and analyst recommendations.

Earnings and Valuation

This table compares Haemonetics and ICU Medical's gross revenue, earnings per share (EPS) and valuation.

ICU Medical has higher revenue and earnings than Haemonetics. ICU Medical is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Haemonetics has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500. Comparatively, ICU Medical has a beta of 0.72, suggesting that its share price is 28% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and target prices for Haemonetics and ICU Medical, as provided by MarketBeat.

Haemonetics presently has a consensus target price of $144.80, suggesting a potential upside of 23.51%. ICU Medical has a consensus target price of $240.50, suggesting a potential upside of 15.69%. Given Haemonetics' higher possible upside, research analysts plainly believe Haemonetics is more favorable than ICU Medical.

Institutional and Insider Ownership

96.2% of Haemonetics shares are owned by institutional investors. Comparatively, 91.5% of ICU Medical shares are owned by institutional investors. 1.6% of Haemonetics shares are owned by insiders. Comparatively, 10.9% of ICU Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Haemonetics and ICU Medical's net margins, return on equity and return on assets.

Summary

Haemonetics beats ICU Medical on 8 of the 13 factors compared between the two stocks.

ICU Medical (NASDAQ:ICUI) and Quidel (NASDAQ:QDEL) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations and valuation.

Volatility and Risk

ICU Medical has a beta of 0.72, suggesting that its share price is 28% less volatile than the S&P 500. Comparatively, Quidel has a beta of 0.45, suggesting that its share price is 55% less volatile than the S&P 500.

Profitability

This table compares ICU Medical and Quidel's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent ratings and target prices for ICU Medical and Quidel, as provided by MarketBeat.

ICU Medical currently has a consensus target price of $240.50, suggesting a potential upside of 15.69%. Quidel has a consensus target price of $262.75, suggesting a potential upside of 103.60%. Given Quidel's higher possible upside, analysts clearly believe Quidel is more favorable than ICU Medical.

Insider and Institutional Ownership

91.5% of ICU Medical shares are held by institutional investors. Comparatively, 84.0% of Quidel shares are held by institutional investors. 10.9% of ICU Medical shares are held by company insiders. Comparatively, 14.1% of Quidel shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares ICU Medical and Quidel's gross revenue, earnings per share and valuation.

ICU Medical has higher revenue and earnings than Quidel. ICU Medical is trading at a lower price-to-earnings ratio than Quidel, indicating that it is currently the more affordable of the two stocks.